Characteristics of the 3 groups of patients based on their LAC reactivity
| Characteristic . | Group 1: β2GPI-dependent LAC . | Group 2: β2GPI-independent LAC . | Group 3: No LAC . |
|---|---|---|---|
| Total, no. | 11 | 12 | 10 |
| Females, no. | 10 | 11 | 10 |
| Median age, y | 31 | 35 | 30 |
| Primary APS, no. | 3 | 0 | 0 |
| Secondary APS, no. | 8 | 4 | 1 |
| Clinical symptoms | |||
| Thrombosis, no. | 11 | 4 | 2 |
| Arterial thrombosis, no. | 3 | 3 | 1 |
| Venous thrombosis, no. | 8 | 2 | 1 |
| Antibody distribution | |||
| Anti-β2GPI antibodies, no. | 11 | 3 | 1 |
| IgG, no. | 11 | 3 | 1 |
| IgM, no. | 4 | 0 | 0 |
| Antidomain 1 IgG antibodies, no. | 11 | 0 | 0 |
| Antiprothrombin antibodies, no. | 9 | 8 | 4 |
| IgG, no. | 8 | 5 | 3 |
| IgM, no. | 8 | 3 | 1 |
| aCL antibodies, no. | 10 | 7 | 3 |
| IgG, no. | 10 | 6 | 3 |
| IgM, no. | 8 | 3 | 2 |
| Characteristic . | Group 1: β2GPI-dependent LAC . | Group 2: β2GPI-independent LAC . | Group 3: No LAC . |
|---|---|---|---|
| Total, no. | 11 | 12 | 10 |
| Females, no. | 10 | 11 | 10 |
| Median age, y | 31 | 35 | 30 |
| Primary APS, no. | 3 | 0 | 0 |
| Secondary APS, no. | 8 | 4 | 1 |
| Clinical symptoms | |||
| Thrombosis, no. | 11 | 4 | 2 |
| Arterial thrombosis, no. | 3 | 3 | 1 |
| Venous thrombosis, no. | 8 | 2 | 1 |
| Antibody distribution | |||
| Anti-β2GPI antibodies, no. | 11 | 3 | 1 |
| IgG, no. | 11 | 3 | 1 |
| IgM, no. | 4 | 0 | 0 |
| Antidomain 1 IgG antibodies, no. | 11 | 0 | 0 |
| Antiprothrombin antibodies, no. | 9 | 8 | 4 |
| IgG, no. | 8 | 5 | 3 |
| IgM, no. | 8 | 3 | 1 |
| aCL antibodies, no. | 10 | 7 | 3 |
| IgG, no. | 10 | 6 | 3 |
| IgM, no. | 8 | 3 | 2 |
Numbers indicate absolute numbers of patients, unless otherwise indicated. Characteristics of the healthy controls are provided in “Patients, materials, and methods.”